Mindfulness, Optimism, and Resilience for Perinatal Health and Equity Study (MORPHE)

August 18, 2025 updated by: Nina Ayala
Dispositional optimism (the general assumption that more good things than bad will occur across various life domains) has been tied to improved somatic and mental health outcomes. Dispositional optimism is malleable, although prior interventions have been time and resource intensive and thus are not well-tailored to the peripartum period. The purpose of this pilot study is to evaluate the feasibility and acceptability of a pregnancy-oriented mindfulness phone application (Expectful) versus standard care among first-time mothers with low dispositional optimism in early pregnancy. Other aims include evaluating the impact of Expectful use on dispositional optimism, adverse pregnancy outcomes (cesarean delivery, hypertensive disorders of pregnancy, and gestational diabetes) and postpartum post-traumatic stress symptoms.

Study Overview

Status

Recruiting

Detailed Description

This randomized clinical trial of nulliparous women with low dispositional optimism in early pregnancy seeks to determine whether use of a pregnancy-oriented digital mindfulness application will be feasible and acceptable and show preliminary evidence of efficacy in improving dispositional optimism, reducing adverse perinatal outcomes and improving postpartum post-traumatic stress symptoms.

This pilot will include 100 women recruited from the obstetrical service at Women and Infants Hospital of Rhode Island. Women will be included if they are nulliparous, have a singleton pregnancy at <20 weeks gestational age, speak English and have low dispositional optimism (a score of ≤14 on the validated, Revised Life Orientation Test). Eligible participants will be randomized to either using the digital app Expectful or standard pregnancy care.

Women will be randomized with equal probability to the intervention group using block randomization stratified by race/ethnicity (Hispanic, non-Hispanic White/Other or non-Hispanic Black).

Women in the mindfulness training arm will complete 8 weeks of daily mindfulness training exercises using Expectful. Women in the standard care group will receive standard pregnancy and postpartum care. Pregnancy and labor management will be at the discretion of each participant's obstetric provider.

Participants in both groups will be asked to complete 4 questionnaires: one at enrollment, a post-intervention one at 8 weeks, at the time of delivery and at 6-8 weeks postpartum. Half of the participants in each arm (total n=50), will be asked to complete a qualitative, semi-structured interview on the role of optimism and other resilience factors in pregnancy.

Study Type

Interventional

Enrollment (Estimated)

100

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Nina K Ayala, MD, MSCR
  • Phone Number: 43435 401-274-1100
  • Email: nayala@carene.org

Study Contact Backup

Study Locations

    • Rhode Island
      • Providence, Rhode Island, United States, 02905
        • Recruiting
        • Obstetrics and Gynecology Care Center
        • Contact:
          • Nina K. Ayala, MD
      • Providence, Rhode Island, United States, 02905
        • Recruiting
        • Prenatal Diagnosis Center
        • Contact:
          • Nina K. Ayala, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Able to provide informed consent
  • English speaking
  • Nulliparous (no prior delivery at or greater than 20w0d gestation)
  • Pregnant with singleton fetus
  • <20w0d gestation
  • Low dispositional optimism (score </= 14 on the Revised Life Orientation Test)
  • Owns a smart phone

Exclusion Criteria:

  • Plan to deliver at another institution
  • Ongoing (≥1/week) mind-body practice including mindfulness training, meditation or yoga
  • Pre-gestational hypertensive disorder
  • Pre-gestational diabetes mellitus

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: App-based mindfulness training
App-based daily mindfulness training Standard prenatal and pregnancy care
Once daily, 5-10 minute mindfulness exercises for 8 week intervention period using the existing perinatal mindfulness application Expectful
No Intervention: Usual Care
Standard prenatal and pregnancy care

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of participants completing the assigned mindfulness exercises
Time Frame: 8-week intervention period
The intervention will be considered feasible if ≥75% participants complete >50% of the assigned daily mindfulness exercises over the 8-week intervention period
8-week intervention period
Intervention acceptability
Time Frame: After 8 week intervention period, approximately 16-28 weeks gestation.
The intervention will be considered acceptable if ≥75% report "satisfied" or "very satisfied" on a post-intervention consumer satisfaction survey with a 5-point Likert scale from very unsatisfied to very satisfied.
After 8 week intervention period, approximately 16-28 weeks gestation.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Dispositional optimism
Time Frame: Study enrollment and 6-12 weeks postpartum
Change in dispositional optimism score (on validated Revised Life Orientation Test, scale range 0-24, higher scores indicate higher optimism) between enrollment and postpartum assessments
Study enrollment and 6-12 weeks postpartum
Cesarean delivery
Time Frame: Delivery
Binary yes/no
Delivery
Hypertensive disorder of pregnancy
Time Frame: 6-12 weeks postpartum
Binary yes/no; includes gestational hypertension, pre-eclampsia with or without severe features, HELLP syndrome or eclampsia
6-12 weeks postpartum
Gestational diabetes mellitus
Time Frame: Delivery
Binary yes/no
Delivery
Preterm birth
Time Frame: Delivery
Binary yes/no; Delivery between 20w0d and 36w6d gestation
Delivery
Traumatic birth
Time Frame: Delivery
Binary yes/no; Self-reported experience of birth as traumatic given concern for life or well-being of self or infant
Delivery
Postpartum post-traumatic stress symptoms
Time Frame: 6-12 weeks postpartum
Continuous scale score using the PTSD Checklist for the Diagnostic and Statistical Manual of Mental Disorders (PCL-5, scale range 0-80, higher scores indicate worse post-traumatic stress symptoms)
6-12 weeks postpartum

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 20, 2024

Primary Completion (Estimated)

April 1, 2026

Study Completion (Estimated)

October 1, 2026

Study Registration Dates

First Submitted

April 17, 2023

First Submitted That Met QC Criteria

April 28, 2023

First Posted (Actual)

May 3, 2023

Study Record Updates

Last Update Posted (Actual)

August 24, 2025

Last Update Submitted That Met QC Criteria

August 18, 2025

Last Verified

August 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1983168

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Postpartum Psychiatric Disorders

Clinical Trials on Digital Mindfulness Training

Subscribe